Laksh Aithani, CHARM Therpeutics CEO
June 9, 2022 03:00 AM EDTUpdated 06:47 AM
Financing
Startups

Big names, big back­ers: David Bak­er joins Or­biMed, F-Prime, Khosla and oth­ers as pro­tein-lig­and biotech launch­es

Paul Schloesser

Associate Editor

David Bak­er, one of the biggest names in the pro­tein de­sign space with mul­ti­ple sci­en­tif­ic prizes, his own in­sti­tute at the Uni­ver­si­ty of Wash­ing­ton and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times